DURHAM, NC, December 13, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. HUMAa clinical-stage biotechnology platform company developing commercial-scale universally implantable bioengineered human tissue, today announced that it will host a Key Opinion Leader (KOL) webinar on Thursday about its proprietary human acellular vessels (HAV) in the treatment of Vascular Trauma During War, December 15, 2022 at 8:00 am ET.

The event will include presentations from several Ukrainian surgeons discussing the use of the HAV to treat multiple cases of war-related traumatic injuries. The formal presentations will be followed by a question and answer session. To register for the event, please click here.

The HAV has received priority status for the treatment of vascular injuries from the US Secretary of Defense. The HAV is extremely resistant to infection and was designed to provide a standard availability for repairing injured blood vessels. The HAV is manufactured in a bioreactor bag that can be shipped and stored so that the HAV is immediately available when needed to repair vascular injuries. The HAV was designed to address the long-standing limitations of acute injury repair and replacement of vascular tissue in both civilian and combat settings.

The HAV results contained in these presentations are part of Humacyte’s humanitarian response initiative in Ukraine. In June 2022, Humacyte provided HAVs to several frontline Ukrainian hospitals to treat patients with traumatic vascular injuries sustained during the conflict. In the United States, Humacyte is also evaluating the HAV for the treatment of civilian vascular trauma in a Phase 2/3 clinical trial. Patients enrolled in the Phase 2/3 trial do not have a suitable autologous vein to repair their traumatic injuries, and many have contaminated wounds that make use of synthetic conduits unsuitable. The HAV is an investigational product and has not been approved for sale by the FDA, Ukraine’s Ministry of Health.